Literature DB >> 26765938

Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients.

Timothy B Depp1, Kathleen A McGinnis, Kevin Kraemer, Kathleen M Akgün, E Jennifer Edelman, David A Fiellin, Adeel A Butt, Stephen Crystal, Adam J Gordon, Matthew Freiberg, Cynthia L Gibert, David Rimland, Kendall J Bryant, Kristina Crothers.   

Abstract

OBJECTIVE: To determine the association between HIV infection and other risk factors for acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
DESIGN: Longitudinal, national Veterans Aging Cohort Study including 43 618 HIV-infected and 86 492 uninfected veterans.
METHODS: AECOPD was defined as an inpatient or outpatient COPD ICD-9 diagnosis accompanied by steroid and/or antibiotic prescription within 5 days. We calculated incidence rate ratios (IRR) and 95% confidence intervals (CI) for first AECOPD over 2 years and used Poisson regression models to adjust for risk factors.
RESULTS: Over 234 099 person-years of follow-up, 1428 HIV-infected and 2104 uninfected patients had at least one AECOPD. HIV-infected patients had an increased rate of AECOPD compared with uninfected (18.8 vs. 13.3 per 1000 person-years, P < 0.001). In adjusted models, AECOPD risk was greater in HIV-infected individuals overall (IRR 1.54; 95% CI 1.44-1.65), particularly in those with more severe immune suppression when stratified by CD4 cell count (cells/μl) compared with uninfected (HIV-infected CD4 < 200: IRR 2.30, 95% CI 2.10-2.53, HIV-infected CD4 ≥ 200-349: IRR 1.32, 95% CI 1.15-1.51, HIV-infected CD4 ≥ 350: IRR 0.99, 95% CI 0.88-1.10). HIV infection also modified the association between current smoking and alcohol-related diagnoses with risk for AECOPD such that interaction terms for HIV and current smoking or HIV and alcohol-related diagnoses were each significantly associated with AECOPD.
CONCLUSION: HIV infection, especially with lower CD4 cell count, is an independent risk factor for AECOPD. Enhanced susceptibility to harm from current smoking or unhealthy alcohol use in HIV-infected patients may also contribute to the greater rate of AECOPD.

Entities:  

Mesh:

Year:  2016        PMID: 26765938      PMCID: PMC5719864          DOI: 10.1097/QAD.0000000000000940

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  67 in total

Review 1.  The prognostic variables predictive of mortality in patients with an exacerbation of COPD admitted to the ICU: an integrative review.

Authors:  B Messer; J Griffiths; S V Baudouin
Journal:  QJM       Date:  2011-11-08

2.  Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality.

Authors:  Prasadini N Perera; Edward P Armstrong; Duane L Sherrill; Grant H Skrepnek
Journal:  COPD       Date:  2012-03-12       Impact factor: 2.409

Review 3.  Changing global epidemiology of pulmonary manifestations of HIV/AIDS.

Authors:  Mark W Hull; Peter Phillips; Julio S G Montaner
Journal:  Chest       Date:  2008-12       Impact factor: 9.410

4.  Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study.

Authors:  C R Jenkins; B Celli; J A Anderson; G T Ferguson; P W Jones; J Vestbo; J C Yates; P M A Calverley
Journal:  Eur Respir J       Date:  2011-07-07       Impact factor: 16.671

5.  Alcohol intake is associated with altered pulmonary function.

Authors:  Joseph H Sisson; Julie A Stoner; Debra J Romberger; John R Spurzem; Todd A Wyatt; Joseph Owens-Ream; David M Mannino
Journal:  Alcohol       Date:  2005-05       Impact factor: 2.405

Review 6.  HIV-associated lung infections and complications in the era of combination antiretroviral therapy.

Authors:  Kristina Crothers; Bruce W Thompson; Kathryn Burkhardt; Alison Morris; Sonia C Flores; Philip T Diaz; Richard E Chaisson; Gregory D Kirk; William N Rom; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-06

7.  Resource use and risk factors in high-cost exacerbations of COPD.

Authors:  Jan B Oostenbrink; Maureen P M H Rutten-van Mölken
Journal:  Respir Med       Date:  2004-09       Impact factor: 3.415

8.  Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication.

Authors:  James E Walker; Anthony R Odden; Samithamby Jeyaseelan; Ping Zhang; Gregory J Bagby; Steve Nelson; Kyle I Happel
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

9.  Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era.

Authors:  M Patricia George; Mouhamed Kannass; Laurence Huang; Frank C Sciurba; Alison Morris
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

10.  Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Authors:  Margaret K Pasquale; Shawn X Sun; Frank Song; Heather J Hartnett; Stephen A Stemkowski
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-11-01
View more
  15 in total

1.  Incidence of chronic obstructive pulmonary disease in people with HIV in Ontario, 1996-2015: a retrospective population-based cohort study.

Authors:  Tony Antoniou; Zhan Yao; Janet Raboud; Andrea S Gershon
Journal:  CMAJ Open       Date:  2020-02-18

2.  Markers of chronic obstructive pulmonary disease are associated with mortality in people living with HIV.

Authors:  Matthew Triplette; Amy Justice; Engi F Attia; Janet Tate; Sheldon T Brown; Matthew Bidwell Goetz; Joon W Kim; Maria C Rodriguez-Barradas; Guy W Soo Hoo; Cherry Wongtrakool; Kathleen Akgün; Kristina Crothers
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

3.  Factors Associated With Progression of Lung Function Abnormalities in HIV-Infected Individuals.

Authors:  Yijia Li; Seyed Mehdi Nouraie; Cathy Kessinger; Renee Weinman; Laurence Huang; Ruth M Greenblatt; Eric Kleerup; Lawrence Kingsley; Deborah McMahon; Meghan Fitzpatrick; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

Review 4.  Obstructive Lung Diseases in HIV: A Clinical Review and Identification of Key Future Research Needs.

Authors:  M Bradley Drummond; Ken M Kunisaki; Laurence Huang
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 5.  Non-infectious Pulmonary Diseases and HIV.

Authors:  M Triplette; K Crothers; E F Attia
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

Review 6.  Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons.

Authors:  A Cooper
Journal:  Semin Pediatr Surg       Date:  1995-11       Impact factor: 2.754

Review 7.  ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research.

Authors:  Joyonna Carrie Gamble-George; Christopher T Longenecker; Allison R Webel; David H Au; Arleen F Brown; Hayden Bosworth; Kristina Crothers; William E Cunningham; Kevin A Fiscella; Alison B Hamilton; Christian D Helfrich; Joseph A Ladapo; Amneris Luque; Jonathan N Tobin; Gail E Wyatt
Journal:  Prog Cardiovasc Dis       Date:  2020-03-19       Impact factor: 8.194

Review 8.  Chronic obstructive pulmonary disease in HIV.

Authors:  Katerina Byanova; Ken M Kunisaki; Joshua Vasquez; Laurence Huang
Journal:  Expert Rev Respir Med       Date:  2020-11-23       Impact factor: 3.772

9.  Incident obstructive lung disease and mortality among people with HIV and a history of injecting drugs.

Authors:  Mariah M Kalmin; Daniel Westreich; Bradley M Drummond; Jing Sun; Shruti H Mehta; Gregory D Kirk
Journal:  AIDS       Date:  2021-07-15       Impact factor: 4.632

Review 10.  HIV and ageing: improving quantity and quality of life.

Authors:  Keri N Althoff; Mikaela Smit; Peter Reiss; Amy C Justice
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.